Kevin Ebata

Kevin Ebata

Auto-generated profile, based on publicly available information

Kevin Ebata

Loxo Oncology, Inc., Stamford, Connecticut

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2018 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
ADAlexander Drilon
Alexander Drilon
TLTheodore W. Laetsch
Theodore W. Laetsch
SKShivaani Kummar
Shivaani Kummar
SDSteven G. DuBois
Steven G. DuBois
ULUlrik N. Lassen
Ulrik N. Lassen
DHDavid M. Hyman
David M. Hyman
Fusions involving one of three tropomyosin receptor kinases (TRK) occur in diverse cancers in children and adults. We evaluated the efficacy and safety of larotrectinib, a highly selective TRK inhibitor, in adults and children who had tumors with these fusions. We enrolled patients with consecutively and prospectively identified TRK fusion–positive cancers, detected by molecular profiling as routinely performed at each site, into one of three protocols: a phase 1 study involving adults, a phase 1–2 study involving children, or a phase 2 study involving adolescents and adults. The primary end point for the combined analysis was the overall response rate according to independent review. Secondary end points included duration of response, progression-free survival, and safety. A total of 55 patients, ranging in age from 4 months to 76 years, were enrolled and treated. Patients had 17 unique TRK fusion–positive tumor types. The overall response rate was 75% (95% confidence interval [CI], 61 to 85) according to independent review and 80% (95% CI, 67 to 90) according to investigator assessment. At 1 year, 71% of the responses were ongoing and 55% of the patients remained progression-free. The median duration of response and progression-free survival had not been reached. At a median follow-up of 9.4 months, 86% of the patients with a response (38 of 44 patients) were continuing treatment or had undergone surgery that was intended to be curative. Adverse events were predominantly of grade 1, and no adverse event of grade 3 or 4 that was considered by the investigators to be related to larotrectinib occurred in more than 5% of patients. No patient discontinued larotrectinib owing to drug-related adverse events. Larotrectinib had marked and durable antitumor activity in patients with TRK fusion–positive cancer, regardless of the age of the patient or of the tumor type. (Funded by Loxo Oncology and others; ClinicalTrials.gov numbers, NCT02122913, NCT02637687, and NCT02576431.)

30 June 2013 in Nature
Verified
Journal Article
Open access
PDF file
KBKathryn Blaschke
Kathryn Blaschke
KEKevin T. Ebata
Kevin T. Ebata
MKMohammad M. Karimi
Mohammad M. Karimi
JZJorge A. Zepeda-Martínez
Jorge A. Zepeda-Martínez
PGPreeti Goyal
Preeti Goyal
MRMiguel Ramalho-Santos
Miguel Ramalho-Santos
Vitamin C is a direct regulator of Tet enzyme activity and DNA methylation fidelity in mouse ES cells; addition of vitamin C promotes Tet activity, increases 5-hydroxymethlycytosine (5hmC) and DNA demethylation of many gene promoters, upregulates demethylated germline genes, and induces a state that more closely approximates that of the inner cell mass of the blastocyst. The Tet enzymes regulate DNA methylation by converting 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) and other oxidized variants. Here vitamin C, a cofactor of enzymes of the same family as the Tets, is shown to be a direct regulator of Tet activity in mouse embryonic stem cells, which are typically cultured in the absence of vitamin C. Addition of vitamin C to the culture medium leads to increased 5hmC content and the demethylation of numerous gene promoters. The remodelled DNA methylation and gene expression patterns resemble the DNA demethylation that occurs in the inner cell mass of the early embryo. DNA methylation is a heritable epigenetic modification involved in gene silencing, imprinting, and the suppression of retrotransposons1. Global DNA demethylation occurs in the early embryo and the germ line2,3, and may be mediated by Tet (ten eleven translocation) enzymes4,5,6, which convert 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC)7. Tet enzymes have been studied extensively in mouse embryonic stem (ES) cells8,9,10,11,12, which are generally cultured in the absence of vitamin C, a potential cofactor for Fe(ii) 2-oxoglutarate dioxygenase enzymes such as Tet enzymes. Here we report that addition of vitamin C to mouse ES cells promotes Tet activity, leading to a rapid and global increase in 5hmC. This is followed by DNA demethylation of many gene promoters and upregulation of demethylated germline genes. Tet1 binding is enriched near the transcription start site of genes affected by vitamin C treatment. Importantly, vitamin C, but not other antioxidants, enhances the activity of recombinant Tet1 in a biochemical assay, and the vitamin-C-induced changes in 5hmC and 5mC are entirely suppressed in Tet1 and Tet2 double knockout ES cells. Vitamin C has a stronger effect on regions that gain methylation in cultured ES cells compared to blastocysts, and in vivo are methylated only after implantation. In contrast, imprinted regions and intracisternal A particle retroelements, which are resistant to demethylation in the early embryo2,13, are resistant to vitamin-C-induced DNA demethylation. Collectively, the results of this study establish vitamin C as a direct regulator of Tet activity and DNA methylation fidelity in ES cells.

27 August 2020 in New England Journal of Medicine
Verified
Journal Article
Closed access
LWLori J. Wirth
Lori J. Wirth
ESEric Sherman
Eric Sherman
BRBruce Robinson
Bruce Robinson
BSBenjamin Solomon
Benjamin Solomon
HKHyunseok Kang
Hyunseok Kang
MCMaria E. Cabanillas
Maria E. Cabanillas
RET mutations occur in 70% of medullary thyroid cancers, and RET fusions occur rarely in other thyroid cancers. In patients with RET-altered thyroid cancers, the efficacy and safety of selective RET inhibition are unknown.

27 August 2020 in New England Journal of Medicine
Verified
Journal Article
Closed access
ADAlexander Drilon
Alexander Drilon
GOGeoffrey R. Oxnard
Geoffrey R. Oxnard
DTDaniel S.W. Tan
Daniel S.W. Tan
HLHerbert H.F. Loong
Herbert H.F. Loong
MJMelissa Johnson
Melissa Johnson
VSVivek Subbiah
Vivek Subbiah
RET fusions are oncogenic drivers in 1 to 2% of non–small-cell lung cancers (NSCLCs). In patients with RET fusion–positive NSCLC, the efficacy and safety of selective RET inhibition are unknown.

1 May 2018 in The Lancet Oncology
Verified
Journal Article
Closed access
TLTheodore Laetsch
Theodore Laetsch
SDSteven G DuBois
Steven G DuBois
LMLeo Mascarenhas
Leo Mascarenhas
BTBrian Turpin
Brian Turpin
NFNoah Federman
Noah Federman
DHDouglas S Hawkins
Douglas S Hawkins

31 August 2017 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
ADAlexander Drilon
Alexander Drilon
RNRamamoorthy Nagasubramanian
Ramamoorthy Nagasubramanian
JBJames F. Blake
James F. Blake
NKNora Ku
Nora Ku
BTBrian B. Tuch
Brian B. Tuch
DHDavid M. Hyman
David M. Hyman
Larotrectinib, a selective TRK tyrosine kinase inhibitor (TKI), has demonstrated histology-agnostic efficacy in patients with TRK fusion–positive cancers. Although responses to TRK inhibition can be dramatic and durable, duration of response may eventually be limited by acquired resistance. LOXO-195 is a selective TRK TKI designed to overcome acquired resistance mediated by recurrent kinase domain (solvent front and xDFG) mutations identified in multiple patients who have developed resistance to TRK TKIs. Activity against these acquired mutations was confirmed in enzyme and cell-based assays and in vivo tumor models. As clinical proof of concept, the first 2 patients with TRK fusion–positive cancers who developed acquired resistance mutations on larotrectinib were treated with LOXO-195 on a first-in-human basis, utilizing rapid dose titration guided by pharmacokinetic assessments. This approach led to rapid tumor responses and extended the overall duration of disease control achieved with TRK inhibition in both patients. Significance: LOXO-195 abrogated resistance in TRK fusion–positive cancers that acquired kinase domain mutations, a shared liability with all existing TRK TKIs. This establishes a role for sequential treatment by demonstrating continued TRK dependence and validates a paradigm for the accelerated development of next-generation inhibitors against validated oncogenic targets. Cancer Discov; 7(9); 963–72. ©2017 AACR. See related commentary by Parikh and Corcoran, p. 934. This article is highlighted in the In This Issue feature, p. 920